Dermata Therapeutics Inc DRMA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the First Quarter 2026
-
Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Application of Dermal Fillers with its Bioneedle Delivery System
-
Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Year Ended 2025
-
Dermata Announces Appointment of Kyra Peckaitis as Vice President, Marketing
Trading Information
- Previous Close Price
- $1.25
- Day Range
- $1.19–1.21
- 52-Week Range
- $1.11–7.85
- Bid/Ask
- $0.00 / $0.00
- Shares Outstanding
- 4.02M
- Market Cap
- $4.75M
- Volume/Avg
- 57,813 / 782,938
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Dermata Therapeutics Inc develops and commercializes dermatology products for the treatment of common skin conditions. It focuses on leveraging prior clinical and technical expertise to develop OTC treatments for conditions such as acne, psoriasis, rosacea, and seborrheic dermatitis. The company is currently developing a once-weekly acne treatment system that utilizes an active ingredient from the OTC monograph in combination with the company's Spongilla technology. It intends to apply its Spongilla technology platform across a range of dermatologic and aesthetic skin applications, including intradermal delivery of botulinum toxin. The company's operates in one segment, which is the business of developing, branding, marketing, and commercializing direct to consumer skincare products.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 9
- Website
- https://www.dermatarx.com
Valuation
|
Metric
|
DRMA
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.74 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
DRMA
Financial Strength
|
Metric
|
DRMA
|
|---|---|
Quick Ratio | 6.60 |
Current Ratio | 7.09 |
Interest Coverage | — |
Quick Ratio
DRMA
Profitability
|
Metric
|
DRMA
|
|---|---|
Return on Assets (Normalized) | −93.84% |
Return on Equity (Normalized) | −117.80% |
Return on Invested Capital (Normalized) | −122.16% |
Return on Assets
DRMA
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Fqcbpllsv | Ykbfsl | $113B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Cfzlzpcb | Ttsffd | $67B | |||
| argenx SE ADR
ARGX
| Xxtfmmfl | Vcw | $55B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Ywtnylyqy | Pqnmrc | $40B | |||
| Royalty Pharma PLC Class A
RPRX
| Lrxftfxys | Wmpskd | $25B | |||
| BioNTech SE ADR
BNTX
| Hjrxkcnc | Rcmft | $22B | |||
| Incyte Corp
INCY
| Nzkgmbhvc | Std | $20B | |||
| Moderna Inc
MRNA
| Zmthqxbz | Hsd | $19B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| Cqmcwslqt | Bxdc | $15B | |||
| BridgeBio Pharma Inc
BBIO
| Fkcmzstp | Qhjd | $13B |
United States